Key Highlights
- Partnership to expand patient access to psycho-oncology services and NGS biomarker testing.
- Free access to Mika’s Digital Therapeutic for oncology-specific fatigue, anxiety, and depression.
- Massive Bio’s AI platform to streamline clinical trial matching and genomic testing.
- Enhanced patient outcomes and experiences with innovative therapies and support.
- Real-world data to inform new therapies and improve patient support services.
Source: Business Wire
Notable Quotes
- “We’re thrilled to partner with Massive Bio to help more patients have more treatment options faster through improved access to genomic testing and matching to clinical trials that could save their lives – and to improve their experiences as they search for and access those treatments.” — Dr. Gandolf Finke, CEO and Founder at Mika Health
- “Our partnership marks a significant leap towards global personalized cancer care at a time when too many patients are struggling to find effective treatments.” — Dr. Selin Kurnaz, PhD, Co-Founder and CEO at Massive Bio
- “As cancer treatments become more sophisticated and personalized, patients are increasingly unable to identify and access the targeted therapy and psycho-oncological support they need.” — Mark Slaughter, Chief Strategy & Growth Officer at Mika Health
SoHC's Take
The collaboration between Massive Bio and Mika Health represents a significant advancement in personalized oncology care. By integrating AI-driven solutions with comprehensive digital therapeutic support, this partnership aims to bridge critical gaps in patient care, ensuring that more individuals have timely access to both physical and mental health resources. The enhanced accessibility to NGS biomarker testing and clinical trials will likely accelerate the identification of effective treatments, improving patient outcomes and overall well-being. This partnership not only highlights the importance of personalized medicine but also the need for holistic approaches that address both the physical and emotional challenges faced by cancer patients.
